切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (06) : 616 -619. doi: 10.3877/cma.j.issn.1674-3946.2020.06.023

所属专题: 文献

论著

甲状腺癌术后碘131联合甲状腺激素应用效果分析
王勇1,(), 王玲2   
  1. 1. 441400 湖北襄阳,宜城市人民医院普一科
    2. 441021 湖北襄阳,襄阳市中心医院普外科
  • 收稿日期:2020-02-20 出版日期:2020-12-26
  • 通信作者: 王勇

Analysis of the effect of iodine 131 combined with thyroid hormone after thyroid cancer surgery

Yong Wang1,(), Ling Wang2   

  1. 1. The first Department of general surgery, Yicheng people's Hospital, Hubei Xiangyang 441400, China
    2. General surgery, Xiangyang city center hospital, Hubei Xiangyang 441021, China
  • Received:2020-02-20 Published:2020-12-26
  • Corresponding author: Yong Wang
  • About author:
    Corresponding author: Wang Yong, Email:
  • Supported by:
    National Natural Science Foundation of China(81360328)
引用本文:

王勇, 王玲. 甲状腺癌术后碘131联合甲状腺激素应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2020, 14(06): 616-619.

Yong Wang, Ling Wang. Analysis of the effect of iodine 131 combined with thyroid hormone after thyroid cancer surgery[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(06): 616-619.

目的

分析甲状腺癌术后碘131联合甲状腺激素应用效果。

方法

回顾性分析2016年6月至2019年7月间收治的196例甲状腺癌患者的临床资料。按术后围术期不同治疗方案分为两组,即联合组(n=98),采用碘131联合甲状腺激素治疗;常规组(n=98),采用甲状腺激素治疗;采用SPSSS23.0统计软件处理数据,两组肿瘤相关因子、乳腺癌转移抑制基因1(BRMSl )和细胞缝隙连接蛋白43(Cx43)阳性表达率等计量资料以(±s)表示,采取独立t检验;残余甲状腺组织清除率等计数资料采取χ2检验;P<0.05为差异有统计学意义。

结果

联合组用药3个月后残余甲状腺组织清除率62.2%高于常规组的46.9%;P53、Fas及TNF-ɑ表达高于常规组(P<0.05)。联合组用药后BRMSl和Cx43阳性表达率分别为92.9%、94.9%高于常规组的81.6%、80.6%(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。

结论

甲状腺癌手术患者采用碘131联合甲状腺激素治疗,能够提高BRMS1和Cx43蛋白表达阳性率,促使残余甲状腺组织清除,临床价值高,值得应用。

Objective

Analysis of the effect of iodine 131 combined with thyroid hormone after thyroid cancer surgery.

Methods

Clinical data of 196 patients with thyroid cancer admitted to our hospital between June 2016 and July 2019 were retrospectively analyzed. According to different postoperative treatment options, the patients were divided into two groups: the combined group (n=98) was treated with iodine 131 combined with thyroid hormone during the perioperative period; the conventional group (n=98) was treated with thyroid hormone during the perioperative period. Spsss23.0 statistical software was used to process the data. The positive expression rate of tumor related factors, breast cancer metastasis suppressor gene 1 (BRMSl) and gap junction protein 43 (Cx43) in the two groups were expressed by (±s), and independent t test was used; the count data of residual thyroid tissue clearance rate was tested by χ2 test; P<0.05 was statistically significant.

Results

The clearance rate of residual thyroid tissue in the combined group (62.2%) was higher than that in the conventional group (46.9%), and the expression of p53, Fas and TNF-α was higher than that in the conventional group (P<0.05). The positive expression rates of breast cancer metastasis suppressor gene 1 (BRMSl) and cell gap junction protein 43 (Cx43) in the combination group were 92.9% and 94.9%, respectively, higher than those in the conventional group, 81.6% and 80.6%, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion

Treatment of thyroid cancer patients with iodine 131 combined with thyroid hormone can increase the positive rate of BRMS1 and Cx43 protein expression and promote the removal of residual thyroid tissue. It has high clinical value and is worthy of application.

表1 196例甲状腺癌患者术后不同治疗方案两组患者基本资料比较(例)
表2 196例甲状腺癌患者术后不同治疗方案两组用药前、用药3个月后肿瘤相关因子(±s)
表3 196例甲状腺癌患者术后不同治疗方案两组BRMS1、Cx43阳性表达率[例(%)]
[1]
Li W, Li F, Lei WW,et al.TRIM30 modulates Interleukin-22-regulated papillary thyroid Cancer cell migration and invasion by targeting Sox17 for K48-linked Polyubiquitination[J].Cell Commun Signal,2019, 17(1): 162.
[2]
郑立春,张腾,胡厚洋,等.非远处转移分化型甲状腺癌低剂量131I清甲治疗疗效分析[J].中华核医学与分子影像杂志,2018, 38(3): 160-163.
[3]
Kim H, Park SY, Jung J,et al.Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer[J].Sci Rep,2019, 9(1): 18745.
[4]
林润龙,于璟.分化型甲状腺癌患者放射性碘治疗前低碘准备的研究进展[J]. 中华核医学与分子影像杂志,2019, 39(3): 182-186.
[5]
武鸿文,段云,赵力威,等.分化型甲状腺癌术后131I清甲疗效相关影响因素分析[J].现代肿瘤医学,2016, 24(18): 2878-2881.
[6]
中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华核医学与分子影像杂志,2013, 33(2): 96-115.
[7]
Villalba NL, Saint-Mezard V, Ortiz MBA, et al. [Spinalcord compression secondary to metastases from a non-previous diagnosed thyroid cancer][J]. Rev Med Liege,2020, 75(4): 201-202.
[8]
伍波,樊友本.我国甲状腺癌治疗现状:不足、不规范和过度并存[J].中华内科杂志,2017, 56(1): 11-14.
[9]
唐润薇.抑制剂量的甲状腺激素对40例分化型甲状腺癌患者骨生化和骨密度的影响[J].药物评价研究,2016, 39(5): 821-824.
[10]
廖安迪,张王峰,胡达堂,等.促甲状腺激素抑制疗法对分化型甲状腺癌患者术后复发率及转移率的影响[J].实用临床医药杂志,2016, 20(17): 100-102.
[11]
姜立新,初海迪,郑海涛. 促甲状腺激素受体与甲状腺癌的研究进展[J]. 中华内分泌外科杂志,2016, 10(1): 74-77.
[12]
罗艳,胡桂英,李颖,等.促甲状腺激素和甲状腺自身抗体在分化型甲状腺癌患者中的表达[J].安徽医学,2017, 38(1): 60-61, 62.
[13]
林岩松.分化型甲状腺癌的碘-131治疗现状和进展[J]. 中华耳鼻咽喉头颈外科杂志,2019, 54(1): 62-68.
[14]
许飞,汤玲琳,袁红,等.分化型甲状腺癌患者碘治疗前肝功能、血脂及血常规水平变化[J].上海交通大学学报(医学版), 2018, 38(6): 632-636.
[15]
王玉龙,邢建武.放射性131碘辅助治疗对80例甲状腺全切除术乳头状甲状腺癌患者预后的影响研究[J].黑龙江医学,2019, 43(3): 199-200.
[16]
王峥嵘,张若曦.碘摄入量与甲状腺癌发生情况的关系研究[J].中国地方病防治杂志,2016, 31(6): 650-651.
[17]
蒋婷,汪君如,张玮,等.分化型甲状腺癌患者术后碘131治疗的不良反应护理[J].华西医学,2016, 31(4): 747-749.
[18]
任章霞,张帆.甲状腺手术联合131^I治疗对甲状腺癌的临床疗效及BRMS1 Cx43蛋白的影响[J].安徽医学,2018, 39(6): 706-710.
[19]
魏灿,张艳斌,应全胜,等.乳腺癌转移抑制基因和骨桥蛋白在前列腺癌组织的表达及其临床意义[J].中华实验外科杂志,2018, 35(12): 2193-2195.
[20]
潘中亚,龙行华.乳腺癌转移抑制基因1表达与肿瘤发生发展相关性的Meta分析[J]. 国际肿瘤学杂志,2016, 43(8): 603-608.
[21]
段佐平,廖荣波,杨显金,等.甲状腺癌组织中Skp2和Cx43的表达与患者临床病理特征的关系[J/CD].中华普外科手术学杂志(电子版), 2019, 13(3): 266-269.
[1] 苏永涛, 王春雷, 徐广琪, 关中正, 焦伟, 隋颖. 胫骨骨膜牵张术联合富血小板血浆对治疗糖尿病足溃疡的疗效观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(03): 238-244.
[2] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[3] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[4] 麻紫月, 王贞文, 张强, 赵代伟, 张翊伦. 右侧喉不返神经1例报告[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 115-116.
[5] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[6] 田文. 甲状腺癌功能性根治颈淋巴结清扫术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 482-482.
[7] 王宇, 徐芳泉, 周旋, 姚晓峰, 李强. 不断提高分化型甲状腺癌根治性切除规范化[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 473-476.
[8] 孙辉, 李长霖. 分化型甲状腺癌根治性切除术中的关键考量与策略[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 477-481.
[9] 高一飞, 刘根祥, 孙长华, 周广军. 喉返神经监测在无充气腋窝入路腔镜单侧甲状腺切除+中央区淋巴结清扫术中的应用效果[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 483-486.
[10] 李云龙, 夏旭良, 江志强, 刘伟, 刘凯, 唐立, 刘昊中, 张思远. 三种方法治疗分化型甲状腺癌的临床疗效[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 487-489.
[11] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[12] 谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[13] 何羽. 腔镜微创手术治疗分化型甲状腺癌的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 456-458.
[14] 宋红霞, 吴玩呈. 内镜下甲状腺手术切口入路发展的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 470-472.
[15] 游涛建, 任林, 马宇. cT1-2N0期PTMC经口腔前庭入路腔镜甲状腺切除术后引流与否的可行性研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 311-314.
阅读次数
全文


摘要